# TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

> **NCT05111366** · PHASE2 · UNKNOWN · sponsor: **Xianhai Mao** · enrollment: 37 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Adjuvant Therapy

## Interventions

- **DRUG:** TQB2450 injection
- **DRUG:** Anlotinib hydrochloride capsules

## Key facts

- **NCT ID:** NCT05111366
- **Lead sponsor:** Xianhai Mao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-06
- **Primary completion:** 2024-01-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2022-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111366, "TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05111366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*